What does Upstream Bio, Inc. do?

Upstream Bio, Inc. is a public company in the Pharmaceutical Preparations industry, incorporated in DE. It is registered with the SEC under CIK 0002022626 and trades on NASDAQ under the ticker UPB.

What is Upstream Bio, Inc.'s annual revenue?

Upstream Bio, Inc. reported $2.85M in revenue for fiscal year 2025, according to its 10-K filing with the SEC.

Is Upstream Bio, Inc. profitable?

Upstream Bio, Inc. reported a net loss of $143.44M in FY2025. This figure is sourced from its SEC EDGAR 10-K annual report.

How many SEC filings has Upstream Bio, Inc. made?

Upstream Bio, Inc. has filed 105 documents with the SEC since 2024. These include annual reports (10-K), quarterly reports (10-Q), current event notices (8-K), and insider transaction disclosures (Form 4).

Upstream Bio, Inc.

UPB NASDAQ CIK: 0002022626 Pharmaceutical Preparations Inc. in DE

View on SEC.gov →

Overview All Filings Annual Quarterly Insiders

Recent Filings

All 105 filings →

Form	Description	Date
8-K	8-K	Mar 26, 2026
424B5	424B5	Mar 26, 2026
S-8	S-8	Mar 26, 2026
10-K	10-K	Mar 26, 2026
8-K	8-K	Mar 26, 2026
4	4	Mar 17, 2026
4	4	Mar 17, 2026
4	4	Mar 17, 2026
4	4	Mar 17, 2026
4	4	Mar 17, 2026

Insider Transactions

View all →

Insider	Title	Type	Shares	Owns After	Date
ORBIMED ADVISORS LLC	—	Purchase	660,000 @ $17.00	4,554,873	Oct 15, 2024
Chimovits Erez	—	Purchase	660,000 @ $17.00	4,554,873	Oct 15, 2024

About This Profile

This page aggregates all publicly available SEC EDGAR data for Upstream Bio, Inc.. Financial figures are sourced from XBRL-tagged 10-K annual reports. Insider transactions are sourced from Form 4 filings required within two business days of a transaction.

Key Financials

Revenue: $2.85M (FY2025)
Net Income: ($143.44M) (FY2025)
Total Assets: $353.77M (FY2025)
Operating Income: ($160.36M)

Full financials →

Details

CIK: 0002022626
Ticker: UPB
Exchange: NASDAQ
Incorporated: DE
First Filing: 2024
Total Filings: 105

Pharmaceutical Preparations rankings →